Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			
iling Date		2006-05-19	
irst Named Inventor   Ikuo		TAJIMA et al.	
Art Unit			
xaminer Name			
Monte Number	or	11711.025	

				Attorn	Attorney Docket Number IIZU 025							
				Audin	ey DOC	xet Number 1120 025						
U.S.PATENTS								Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	ssue Date Name of Patentee or Applicant			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	4009674		1977-0	1977-03-01 LADD							
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Ad	dd button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LIC	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		Publication Name of Patentee or Applicant of cited Document			Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olea	ase click the Ad	d butto	n. Add		
				FOREIG	SN PAT	TENT DOCUM	ΕN	NTS		Remove		
Examiner Initial*			Kind Code <sup>4</sup>	Publication Date	A	lame of Patente opplicant of cited occument	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	74			
	1	3-286797	JP		A	1991-12-17	т	「AJIMA et al.		English Abstract		
	2	2003-320189	JP		A	2003-11-11	R	RO et al.		English Abstract		
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ea	se click the Add	button	Add		
NON-PATENT LITERATURE DOCUMENTS Remove												

	Application Number		
NEODWATION DIGGS COURT	Filing Date		2006-05-19
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	lkuo '	TAJIMA et al.
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	IIZU 025

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.		
	1	Relevant portion of International Search Report of corresponding PCT Application PCTI/IP2004/017013.		

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

Examiner Signature Date Considered Date Considered Date Considered PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

See Not Code of USPTO Pearl Documents at ware USPTO.BOX or MPEP 801.64. 2 Enter office that issued the document, by the Inc-latin code (WIPO Standard ST.3). The Uspanese plant document is a wardward of the year of the Emperor must preced in the see all number of the plant document. The Emperor must preced in the see all number of the plant document.

By the Emperor is attended, code as included on the document under WIPO Standard ST.16 Eposition. Pupping in plant a concern make their of English ingruipes translation is attended.

# Application Number Filing Date 2006-05-19 Filing Date 2006-05-19 Filing Date Transmed Inventor Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Attorney Cooket Number Ruso TA/BMA et al. Art Unit Examiner Name Rus

# CERTIFICATION STATEMENT

riease see 37 CFR 1.	.57 and 1.50 to make the a	appropriate selection(s).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

# ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/marcarossi/	Date (YYYY-MM-DD)	2006-05-19
Name/Print	Marc A. Rossi	Registration Number	31923

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.